Biomarkers for screening of lung cancer and pre-neoplastic lesions in a high risk Chilean population by Marta I Adonis et al.
Adonis et al. Biological Research 2014, 47:62
http://www.biolres.com/content/47/1/62RESEARCH ARTICLE Open AccessBiomarkers for screening of lung cancer and
pre-neoplastic lesions in a high risk Chilean
population
Marta I Adonis1*, Jose Díaz1, Veronica R Miranda2, Marco Chahuan3, Alcides Zambrano4, Hugo C Benitez4,
Monica Campos2, Pablo Avaria1, Ulises Urzúa1, Pedro Marín4ˆ, Mariela Gohurdett5, Yasna Cisterna5 and Lionel Gil1Abstract
Background: The mortality of lung cancer (LC), increases each year in the world, in spite of any advances, in
development of new drugs to advance stages of LC. The high incidence of LC has been associated with smoking
habit, genetic diversity and environmental pollution. Antofagasta region has been reported to have the highest LC
mortality rate in Chile and its inhabitants were exposed to arsenic in their drinking water in concentrations as high
as 870 μg/L. Non-invasive techniques such as biomarkers (Automatic Quantitative Cytometry: AQC and DR70) and Auto
Fluorescence Bronchoscopy (AFB) might be potentially useful as a supplementary diagnostic approach and early detection.
Early detection is one of the most important factors to intervene and prevent cancer progression in LC. This is a work of an
ongoing prospective bimodality cancer surveillance study in high risk LC volunteers. Enrolment was done in subjects from
Antofagasta and Metropolitan regions. In addition, we enrolled subjects who were suspected of having lung cancer. AQC,
DR70 and AFB were used as tools in the detection of pre-neoplastic (PNL) and neoplastic lesions (NL).
Results: Half of the samples, classified as suspicious by AFB, were confirmed as metaplasia or dysplasia by histopathology.
For LC, DR70 showed a higher sensitivity (95.8%) and specificity (91.9%) than AQC. However, for PNL AQC showed
a higher sensitivity (91.9%) than DR70 (27.3%), although both with low PPV values. As a pre screener, both biomarkers
might be employed as complementary tools to detect LC, especially as serially combined tests, with a sensitivity
of 60% and a PPV of 65.2%. Additionally, the use of parallel combined tests might support the detection of PNL
(sensitivity 91.2%; PPV 49.1%).
Conclusion: This work adds information on cellular and molecular biomarkers to complement imaging techniques
for early detection of LC in Latin America that might contribute to formulate policies concerning screening of
LC. Supported by INNOVA-CORFO, Chile.
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The high incidence of lung cancer (LC) has been associ-
ated with cigarette smoking, however genetic diversity
and environmental pollution must also be considered as
risk factors, especially in those cities highly exposed to
environmental carcinogens. During 2008, 1.52 million
new LC cases and 1.31 million deaths were reported* Correspondence: madonis@med.uchile.cl
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unless otherwise stated.worldwide [1]. Early detection is one of the most import-
ant factors to prevent cancer progression in lung cancer
(LC). In this context, non-invasive techniques such as
collection of induced sputum samples for conventional
or automatic quantitative cytometry (AQC) and detection
of serum tumour markers might be potentially useful as a
supplementary diagnostic approach.
There were more than 2,500 LC cases and 1,900 LC
related deaths during 2007 in Chile. Between 1990 and
2008, the national mortality rate/100,000 habitants
increased from 10.8 to 14.6 for both genders. For theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Chile) showed a mortality rate of 30.8/100,000, the second
highest mortality rate after skin cancer [2-6]. The mor-
tality rate, might be related with environmental factors,
like to air pollution and or Arsenic exposition. Many
carcinogenic compounds present in cigarette smoke,
have also been identified in airborne particles in differ-
ent cities around the world [7-15] including Santiago. Has
been described that Benzo(a)pyrene (BaP), one of PAHs
associated to cigarette smoke, induce lung cancer through
DNA damage [16-18]. High levels of BaP and individual
host susceptibility might determine a high levels of
diolepoxide (BPDE)-DNA adduct. It has been postu-
lated that natural compounds like arsenic (As), enhance
the BPDE-DNA adduct induced mutagenesis, suggest-
ing that As might act as a co-mutagen to promote the
development of human LC [19-21].
Santiago’s inhabitants have been exposed to high levels
of BaP, reaching the 4.9 ng/m3, during the year 1996 [6].
On the other hand, Antofagasta region had drinking
water arsenic (dw-As) concentration of 90 μg/L before
1958 [22]. During 1958–1970, dw-As concentration
reached 870 μg/L. Since then, As levels have progres-
sively decreased to the new Chilean standard (10 μg/L).
The antecedents of dw-As in the Antofagasta region
shows that during 1956 the region received drinking water
from the Siloli river, with As concentration of 90 μg/L.
Later, the increasing mining activity led to rapid growing
of the population and a new adduction of the Toconce
river, with dw-As concentration of 823 μg/L, causing an
increasing dw-As concentration in the region, exposing
and affecting to more than 300.000 habitants [23].
The implementation of early-detection technologies and
prognostic biomarkers are imperative in Chile, specifically
in cities that are highly exposed to environmental carcino-
gens, like to PAHs and or Arsenic [22,24]. This work has
been done in Antofagasta and Metropolitan regions in
order to evaluate two biomarkers AQC and DR70
(Onko Sure) as tools in detection of LC and detection of
pre-neoplastic lesions related with LC. Previously, the
researchers of this work used the biomarker DR70, as
screening tool of LC in advance stages but not in pre
neoplastic lesions, in a population exposed historically
to As in drinking water, showing that this biomarker
might provide relevant information to identify individuals
with a lung cancer [19,20]. Additionally, the researchers
have been working with sputum specimen in order to
study genomic alterations in a Chilean population with
high risk of LC (manuscript in preparation). Then, AQC
has been considered as complementary tool in order to
have additionally information associated to malignancy of
LC in the same kind of sample (sputum specimen).
AQC, is a quantitative morphometric analysis of the
amount and distribution of DNA in sputum cells usingnormal epithelial cells [25]. Onko-Sure™, is an in vitro diag-
nostic test that has been described to effectively monitor
and/or detect solid cancerous tumours [26,27]. Auto fluores-
cence Bronchoscopy (AFB), is a technique that exploits dif-
ferences in fluorescence properties of normal and abnormal
bronchial mucosal tissues for the detection of preinvasive
and micro-invasive bronchial lesions, which might otherwise
be invisible on White Light Bronchoscopy (WLB) [28-32].
Results
In Santiago 56.7% were current smokers (N = 127),
35.3% were ex-smokers (N = 79) and 8% (N = 18) were
never smokers. For Antofagasta, 37.1% (N = 52) were
current smokers, 36.4% (N = 51) ex-smokers and 26.4%
(N = 37) were never smokers. According to the smoking
index (packages per year, p/y) [33], most of 43% the
volunteers included in this study were classified as
medium (> ½ -20 p/y) or intense (>20 -40 p/y) smokers
from among either current or ex-smokers.
AQC of induced sputum and DR70
Table 1 shows the likelihood of malignancy by AQC
and DR70. For AQC, 27.2% of the subjects showed
an increased likelihood of malignancy and 26.6% an
undetermined likelihood of malignancy (a score of 3.9
< 4.6). Among samples with increased AQC, 15.4% and
11.8% were negative and positive for DR70 (>1 μg/mL),
respectively. Samples with undetermined AQC showed
22.5% and 4.1% of negative and positive DR70 levels;
respectively. Additionally, among 46.2% of AQC samples
that showed decreased likelihood of malignancy, 42.3%
were negative and 3.9% were positive for DR70.
Table 2 shows results related with the bronchoscopy
procedure, applied to 98 volunteers. The WLB (Table 2A)
showed a 23.47%, 61.22%, 3.06% and 12.25% with nor-
mal condition, inflammation, suspicious condition and
LC; respectively. According to WLB, suspicious cases are
related with cancer in situ (CIS), however the Histopath-
ology Assay (HA) classified all of these cases as inflam-
mation. The HA results showed that a high percentage
of the normal cases according to WLB results, were
hyperplasia (56.52%) and metaplasia (21.74%) and only
17.39% of them were truly normal. For the sites that
were recognized to be inflammation on WLB, the HA
confirmed 28.33% of them as inflammation and the rest
were distributed as normal (11.67%), hyperplasia (48.33%)
and metaplasia (6.67%).
On other hand, AFB classified 18.36%, 57.14% and
12.24%of the cases as normal, inflammation and suspi-
cious for LC; respectively (Table 2B). The HA showed
that within of the 18.36% that were classified by AFB
as normal, 22.22% was really normal and the rest were
distributed as inflammation (5.56%), hyperplasia (61.11%)
and metaplasia (11.11%). The inflammations that were





Likehood of malignance DR70 % of sample (N)
Increased Decreased
Increased 27.2 (99) 11.8 (43) 15.4 (56)
Undetermined 26.6 (97) 4.1 (15) 22.5 (82)
Low 46.2 (168) 3.9 (14) 42.3 (154)
Likehood of malignance.
AQC: Increased ≥ 4.6; Undetermined ≥ 3.9 to < 4.6; Low ≤ 3.8.
DR70: Increased ≥ 1.0; Decreased < 1.0.
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HA in 30.35% and the rest were classified as normal,
hyperplasia, metaplasia and dysplasia (12.5%, 50.0%, 5.36%
and 1.79%; respectively).
For the suspicious biopsies (invasive or pre-neoplastic
lesions), according to AFB (12.2%), HA confirmed
33.33% of them as metaplasia and 16.67% as dysplasia.
The rest were classified by HA as inflammation (25.0%)
and hyperplasia (25.0%). Additionally, for the patients
that were suspicious for LC, with the actual diagnosis in
the study and without any treatment or previous add-
itional assays, AFB results confirmed the WLB diagnosis
in 100% [12]. However, only 75% of them (9 cases out of
12) were confirmed by the HA as LC, a 25% were classi-
fied as dysplasia. Additional studies, such as CT, con-
firmed all 12 cases as LC. Therefore, of a total of 98
volunteers with AFB, 42 cases were related with hyper-
plasia (42.9%), nine cases with metaplasia (9.2%), three
cases with dysplasia (3.1%) and 12 cases as LC (12.2%).
AFB identified the PNL (metaplasia and dysplasia) better
than WLB.
Figure 1 shows the overall ROC performance for
DR70 in LC (Figure 1A,) and preneoplastic lesionsTable 2 Relationship between White Light Bronchoscopy (WL
Histopathology Assay (HA)
A
Variable % (N) WLB % (N) Normal Inflammation
Normal 23.47 (23) 17.39 (4) 4.35 (1)
Inflammation (a) 61.22 (60) 11.67 (7) 28.33 (17)
Suspicious (b) 3.06 (3) 0 100 (3)
LC 12.25 (12) 0 0
TOTAL (98) (11) (21)
B
Variable % (N) AFB % (N) Normal Inflammation
Normal 18.36 (18) 22.22 (4) 5.56 (1)
Inflammation (a) 57.14 (56) 12.5 (7) 30.35 (17)
Suspicious (b) 12.25 (12) 0 25.0 (3)
LC 12.25 (12) 0 0
TOTAL 98 11 21
(a): Abnormal or Inflammation (Erythema, swelling or thickening of bronchial muco
(b): Suspicious for pre invasive or preneoplastic lesion for AFB and cancer in situ (CI(PNL) (Figure 1B). The empirical specificity and sensitiv-
ity of this test for LC were 91.87% (95% confidence
interval [CI]: 88.1–94.8%) and 95.83% (95% CI: 78.9–
99.9%); respectively. The Predictive Positive Value (PPV)
was 50.0 (95% CI: 35.1–65.1%) with a Predictive Nega-
tive Value (PNV) of 99.6% (95% CI: 97.8-100%). The
LR + (Positive Likelihood Ratio) was 11.79 (95% CI: 10.8-
12.9%), increasing further with higher thresholds. Ac-
cording to these results, a patient’s positive test result
was considered as someone with 11.8 times higher risk
of the presence of LC, as compared to a normal individ-
ual. In contrast, the LR- for was 0.045 or 1/22 (95% CI:
0.006–0.3%), meaning that a negative test result corre-
sponded with a decrease in the subject’s odds of disease
by a factor of 22. In conclusion, the ROC curve of DR70
for LC was slightly skewed toward higher sensitivity, al-
though both sensitivity and specificity were quite high.
However the LR + and LR- results suggested that the test
identified subjects with higher risk of lung cancer but
did better for ruling out LC. The biomarker DR70
showed a higher sensitivity and specificity than the
marker CYFRA21-1, with a relative high diagnostic value
for lung carcinoma. CYFRA21-1 has showed a sensitivityB) (A), Autofluorescence Broncoscopy (AFB) (B) and
HA % (N)
Hyperplasia Metaplasia Dysplasia LC
56.52 (13) 21.74 (5) 0 0
48.33 (29) 6.67 (4) 5.0 (3) 0
0 0 0
0 0 25.0 (3) 75.0 (9)
(42) (9) (6) (9)
HA% (N)
Hyperplasia Metaplasia Dysplasia LC
61.11 (11) 11.11 (2) 0 0
50.0 (28) 5.36 (3) 1.79 (1) 0
25.0 (3) 33.33 (4) 16.67 (2) 0
0 0 25.0 (3) 75.0 (9)
42 9 6 9
sa, airway inflammation, and Fibrosis) [31].
S) for WLB.
Figure 1 DR70 ROC curve for LC (A) and Pre-neoplastic Lesions related with LC (B).
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patients with malignant pleural effusion [34]. Add-
itionally, a recently study of CYFRAA21-1, in serum
of LC patients, showed a sensitivity and specificity of
46.21% and 97.14%, respectively; showing a higher
sensitivity for Squamous lung cancer (71.43%) than
Adenocarcinoma (29.41%) and Small Cell Lung Can-
cer (12.5%) [35].
For PNL, the test showed a specificity and sensitivity
of 91.87% (95% CI: 88.1–94.3%) and 27.27% (95% CI:
6.0–61.0%); respectively. The Predictive Positive Value
for PNL was 11.5% (95% CI: 2.4–30.2%) and the Predictive
Negative Value was 97.0% (95% CI: 94.2-98.7%). The LR
was 3.36 (95% CI: 1.3-8.8%) and the LR- was 0.79 or
1/1.27 (95% CI: 0.5–1.3%). According to sensitivity,
specificity, PPV, PNV, LR + and LR-, DR70 by itself
might identify patients with PNL with a sensitivity of
27.27%. However, the test might be better in order to
identify subjects with a low likelihood of PNL, with a
specificity of 91.87%.
The Figure 2 shows, the overall ROC performance for
AQC for LC (Figure 2A) and Preneoplastic lesions (PNL)
(Figure 2B). AQC for LC (Figure 2A), showed a sensitivityFigure 2 AQC ROC curve for LC (A) and Pre-neoplastic Lesions relatedand specificity of 64% (95% confidence interval [CI]:
42.5%–82%) and 89.4% (95% confidence interval [CI]:
85.2%–92.7%), allowing detecting and confirming positive
and negative cases with high precision. The PPV, was
34.8% (95% CI: 21.2%–50.4%) with a PNV of 96.6%
(95% CI: 93.6 -98.6). The LR + was 6.04 (95% CI: 4.5-8.1),
increasing further with higher thresholds. According to
these results, a patient’s positive test result would be
someone with 6.04 time higher risk of presence of disease.
In contrast, the LR- was 0.40 or 1/2.5 (95% CI: 0.2– 0.8),
meaning that a negative test result corresponded with
decrease in the subject’s odds of disease by around a
factor of 2.5.
Kemp et al. [25], published for LC, an sensitivity of
40% (95% CI: 35%–46%) and empirical specificity of
91% (95% CI: 89%–93%), with a threshold of 5.0. Our
results, with thresholds of 5.0, showed a sensitivity of 36%
(95% CI: 18%–57.5%) and specificity of 95.76% (95% CI:
92.7%–97.8%).
For PNL, the Figure 2B shows a sensitivity of 90.91%
(95% CI: 58.7%–99.8%) and an empirical specificity of
89.40% (95% CI: 85.2%–92.7%). The PPV for PNL, was
25% (95% CI: 12.6%–41.4%) and the PNV was 99.6%with LC (B).
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increasing further with higher thresholds. In contrast,
the LR- for this threshold was 0.10 or 1/10 (95% CI:
0.02 – 0.7). According to sensibility, sensitivity, PPV,
PNV, LR + and LR-, AQC itself with a threshold of
4.6, might identify LC patients with both high sensi-
tivity (64%) and confirm absence of LC with a high
specificity (89.4%). Additionally, AQC itself might
identify PNL with a sensitivity of 90.91% and also
confirm subjects without PNL, with a high specificity
of 89.40%, with a threshold of 4.6.
Combining (Multiple) testing
In order to improve the diagnostic accuracy, a combin-
ing multiple test was applied as two-test parallel com-
bination and two-test series combination.
Tests performed in parallel for LC, using DR70 and
AQC showed a sensitivity of 92.0% (95% CI: 79.4 -100.0)
and specificity of 80.9% (95% CI: 76.2 -85.7) (Table 3A).
Combining testing in parallel increased the sensitivity of
AQC for LC, since 64.0% to 92.0%, while the PPV
showed a decreasing, since 34.8% to 29.9%. The NPV
showed not significant changes. For DR70, the parallel
testing showed a non significant decreasing of sensitivity
since 95.83% to 92.0% and specificity, since 91.9% to 80.9%.
Additionally, the PPV decreased significantly, since
50.0% to 29.9%. However, the PNV for DR70 showed not
significant changes.
On the other hand, tests performed in parallel for
PNL, using DR70 and AQC showed an increasing of
sensitivity in both assay (DR70 and AQC). For DR70 the
sensitivity increased since 27.3% to 91.23% (95% CI:
83.0 -99.5), while the specificity showed non statically
decreasing; since 91.9% to 80.92% (95% CI: 76.2 -85.7).
AQC didn’t show significant differences with the paral-
lel test both sensitivity and specificity. However, both
test showed a significant increasing in the PPV, since
11.5% for DR70 and 25.0% for AQC to 49.1% for parallel
testing.
Additionally, an illustration of the effects of serial
combination testing is shown in Table 3B for a screen-
ing protocol with DR70 and AQC. The serial testing
for LC, results in decreasing sensitivity, for both test,
especially for DR70, but with and increasing of the
PPV to 65.2% since 50.0% for DR70 and since 34.8% for
AQC. The specificity showed a significant increasing,
since 91.9% for DR70 and 89.4% for AQC to 97.2% (95%
CI: 95.1%–99.3%). PNV didn’t show significant changes
with serial combination. On the other hand, the serial
combination testing for PNL, showed a significant
decreasing of sensitivity for AQC, since 90.9% to
35.1%, and a non significant increasing for DR70.
However, the specificity showed a significant increas-
ing to 97.2% (95% CI: 95.1%–99.3%), since 91.9% forDR70 and since 89.4% for AQC. Additionally, PPV
showed a significant increasing since 11.5% for DR70
and 25.0% for AQC to 71.4.
Discussion
The aim of this study was to explore two biomarkers as
potential tools to manage of lung cancer (LC) risk.
Our results showed that AFB could identify PNL
(metaplasia and dysplasia) better than WLB by its self, in
patients with high likelihood to malignance according
AQC and DR70. The AFB was able to detect 12.25% of
PNL (12 out of 98) in a healthy population, with LC risk,
according to the LC risk survey. Additionally, AQC
might identify PNL with a high sensitivity of 90.91%,
specificity of 89.4% and a PPV of 25.0% and a PNV of
99.6%. According to these results, this test might be bet-
ter confirming subject without PNL, with a high specifi-
city and PNV. For PNL, AQC by itself resulted in a
better sensitivity as compared to DR70 (27.3%). How-
ever, both of them by itself showed low PPV (11.5% for
DR70 and 25% for AQC). Due to the low overall sensi-
tivity of DR70 for PNL, the assay should be used with
AQC to improve the sensitivity, especially as a parallel
combination protocol. A parallel combination would be
able to confirm positivity for PNL, with a sensitivity of
91.2% and a PPV of 49.1%.
For LC, according to sensitivity, PPV, LR + and LR-,
our results showed that DR70 might contribute to the
confirmation of LC diagnosis and identification of the
patients with advanced LC, with a sensitivity of 95.83%
and a PPV of 50%. However, the test would be better in
negativity LC cases with specificity of 91.87% and PNV of
99.6%. Therefore, DR70 might be used mainly as a com-
plementary tool to confirm LC diagnosis and identify
patients with advanced LC. On the other hand, AQC re-
sulted in a high sensitivity (64%) and specificity (89.4%) for
LC with a higher PNV (96.6%) rather than PPV (34.8%).
This finding confirmed that AQC would support in the
detection and confirmation of positive LC cases and espe-
cially discard the presence of malignance, with high preci-
sion (specificity of 89.4% and PNV of 96.6%).
For LC and PNL, both test (AQC and DR70) might
improve the diagnosis of LC, especially as combined
protocols. Parallel combination might be used as com-
plementary tools, mainly as parallel test with a sensitivity
of 92.0% and 91.2% for LC and PNL, respectively and
high specificity.
Conclusion
In conclusion, as a pre-screening tool for LC, both bio-
markers might be employed with a high specificity and
sensitivity as complementary tools to detect LC.
The prevalence for LC and PNL in this population was
3.74%. Although the population studied represented a
Table 3 Combining multiple test as two-test parallel (A) and serial (B) combination
Test A Sensitivity % (95% CI) Specificity % (95% CI) PPV % (95% CI) PNV % (95% CI)
LC PNL LC PNL LC PNL LC PNL
DR70 95.8 (78.9- 99.9) 27.3 (6.0-61.0) 91.9 (88.1-94.8) 91.9 (88.1-94.3) 50.0 (35.1 -65.1) 11.5 (2.4 -30.2) 99.6 (97.8 -100) 97.0 (94.2 -98.7)
AQC 64.0 (42.5- 82.0) 90.9 (58.7-99.8) 89.4 (85.2-92.7) 89.4 (85.2-92.7) 34.8 (21.2 -50.4) 25.0 (12.6 -41.4) 96.6 (93.6 -98.6) 99.6 (97.8 -100)
Parallel combined test 92.0 (74.4 -100) 91.2 (83.0-99.5) 80.92 (76.2-85.7) 80.92 (76.2-85.7) 29.9 (19.0 -40.7) 49.1 (39.1 -59.1) 99.1 (97.7 -100) 97.9 (95.8 -99.9)
Test B Sensitivity % (95% CI) Specificity % (95% CI) PPV % (95% CI) PNV % (95% CI)
LC PNL LC PNL LC PNL LC PNL
DR70 95.8 (78.9- 99.9) 27.3 (6.0-61.0) 91.9 (88.1-94.8) 91.9 (88.1-94.3) 50.0 (35.1 -65.1) 11.5 (2.4 -30.2) 99.6 (97.8 -100) 97.0 (94.2 -98.7)
AQC 64.0 (42.5- 82.0) 90.9 (58.7-99.8) 89.4 (85.2-92.7) 89.4 (85.2-92.7) 34.8 (21.2 -50.4) 25.0 (12.6 -41.4) 96.6 (93.6 -98.6) 99.6 (97.8 -100)
Serial combined test 60.0 (38.8 -81.2) 35.1 (21.8 -48.4) 97.2 (95.1 -99.3) 97.2 (95.1-99.3) 65.2 (43.6 -86.9) 71.4 (52.9 -90.0) 96.5 (94.2 -98.8) 88.1 (84.4 -91.9)
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from this study might be related to the initial step
of volunteer recruitment. These were consisted of:
adequate survey, appropriate selection of biomarkers
and the inclusion of ordinary individuals and clinicians
in the study in order to detect the right candidates with
high risk for LC in both cities, Santiago and Antofagasta.
Finally, it is important to note that although both tests
together might be able to detect and confirm LC and
or PNL, this proposal is not necessarily a diagnostic
improvement but can be used as an additional tool in
the detection of LC or preneoplastic lesions. Screening
tests might be combined to improve the efficiency of LC
or PNL diagnosis.
These results might improve general health standards
by improving the early detection of LC, especially in
high risk people. In addition, this work provides scientific
and clinical information for Chilean health authorities to
include LC in the AUGE government programme, which
provides additional health services for patients. Chile
needs to formulate policies concerning screening for
LC and PNL since there are a lot of benefits in it for
the patients and its costs to the individuals are rea-
sonable while providing a good quality of life for the
patients.
Methods
The study designed as double blind, enrolled people
(364) from the Metropolitan (Santiago city, N = 224) and
Antofagasta (N = 140) regions, with medium or high risk
for LC, according to a LC Risk Survey [36,37]. Healthy
voluntaries, without symptoms and diagnosis of LC,
were male/female, with aged 40 years or older; family
history of LC, non-smokers, ex-smokers and ever smokers;
exposed naturally to environmental air pollution (Santiago)
or to dw-As (Antofagasta) for at least 10 years. In addition,
we enrolled subjects who were suspected of having lung
cancer (N = 24) based on their clinical symptoms, without
diagnosis and treatment at the moment to enter to the
study. These patients did not have previous tests performed
on them such as cytology or CT. After of a healthy control
and interview with a general practitioner, informed consent
was signed and a sputum sample was obtained prospect-
ively using inhalation of nebulised 3% hypertonic saline.
Subjects were instructed to cough. Additionally, blood sera
samples were obtained of each volunteer for determine the
DR70 levels. The concentrations of DR70 in the sera were
obtained from a standard curve, which results from the
extinctions of calibrators provided with the kit.
AQC, was done according to LungSignTM test (Per-
ceptronix Medical Inc.), as described by Kemp et al. [25]
and the sputum generation, was induced with inhalation
of 3% saline solution. The optimum cut-off level for
AQC of 4.6 was determined selecting the point on theROC (Receiver Operating Characteristic) curve which max-
imised both sensitivity and 1–specificity, using MedCalc
statistical software 12.1 (MedCalc Inc., Mariakerke,
Belgium) with 95% confidence intervals. This value was
equivalent to the threshold recommended by Perceptronix
Medical Inc. (threshold = 4.6).
Furthermore, for DR70, serum was separated and
tested along with the calibrators according to AMDL
Diagnostics Onko Sure protocol (Radient Pharmaceuti-
cals) as described in Adonis et al. [19] and Hatton et al.
[38]. The best cutoff values for the DR70 immunoassay
was obtained with the ROC curve analysis using the
MedCalc statistical software 12.1 with 95% confidence
intervals. The threshold of 1.0 was associated with best
sensitivity and 1-specificity and according with the
protocol of Onko Sure protocol. The Youden Index was
used as measure of the ROC curve, in order to get the
effectiveness of diagnostic and select the optimal thresh-
old value (cutoff point) for both markers.
According to AQC and DR70, the voluntaries were
classified with their risk score (low, medium and high).
Participants with positive DR70 test (threshold >1.0), or
an increased likelihood of malignance according to AQC
(threshold ≥4.6) were invited to have an AFB, using the
Onco-LIFE device (Novadaq Inc., Richmond, Canada),
under local anaesthesia. However, some volunteers did
not agree to be included in the AFB procedure and were
studied only with a Computerized Tomography (CT)
and were confirmed for LC or another disease as TBC
or pulmonary emphysema. The bronchoscopic proce-
dures were carried out under local anaesthesia with or
without sedation. The airways were examined by WLB
and then by AFB and the visual findings were classified
as normal (class I: non visual abnormality), abnormal
(class II: airway inflammation, trauma or anatomical
abnormalities), suspicious of malignant change (class III:
areas suggesting moderate dysplasia or severe dysplasia)
and suspicious of invasive tumour or visible tumour
(class IV), as described by Lam et al. [31]. Endobronchial
mucosal biopsies were taken from all areas that were
suspicious under WLB or AFB. In addition, surveillance
biopsies were taken from epithelium with normal ap-
pearance in all subjects. An average of 2–3 biopsies was
taken from each of the participants. In addition to CT,
the pathology assay, in the biopsies collected during the
bronchoscopic procedure, confirmed the final diagnosis
as normal, pre neoplastic lesion (PNL) (metaplasia or
dysplasia) or LC. No adverse events were reported
during the study.
Categorical variables were analysed by Fisher’s exact
test. The sensitivity and specificity were assessed for
each test and was used in analysis as a single test;
two-test parallel combination and two-test series com-
bination [39,40]. Receiver operating characteristic (ROC)
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http://www.biolres.com/content/47/1/62curve analysis was carried out using the MedCalc statis-
tical software 12.1 with 95% confidence intervals.
A logistic regression was used combining both bio-
markers. The diagnostic cut-off value was determined
from ROC curve and the value was compared with
results obtained from parallel testing and serial testing.
Sensitivity, specificity, predictive values (both positive
and negative) and the Youden’s index were calculated for
AQC and DR70 using Epidat 3.1.
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